Document is current
Any future updates will be listed below
-
Authors
Dickson, Samuel P.
Hennessey, Sean
Nicodemus Johnson, Jessie
Knowlton, Newman
Hendrix, Suzanne B.
- License Information
-
More Information
Article History
Received: 2 February 2023
Accepted: 5 May 2023
First Online: 24 May 2023
Declarations
:
: No original data collection was performed for this manuscript.The original source of the data for this manuscript reported, “The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization and Good Clinical Practice guidelines and was approved by ethics committees or institutional review boards at each site. All patients provided written informed consent. An independent data monitoring committee was responsible for monitoring the conduct of the trials, assessing routine safety, and reviewing futility analysis results.”
: Each of the authors is an employee of Pentara Corporation, Suzanne Hendrix being the CEO. Pentara provides consulting for over 30 pharmaceutical, biotech, non-profit and academic groups in the neurodegenerative space including Biogen but had no involvement in the analysis of the Aducanumab studies.
